Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03463187




Registration number
NCT03463187
Ethics application status
Date submitted
22/01/2018
Date registered
13/03/2018
Date last updated
8/08/2023

Titles & IDs
Public title
Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis
Scientific title
A Multi-Center, Randomized, Double-blind, Placebo-controlled, Multi-Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of SHR-1314 With Expanded Dose Finding in Subjects With Moderate-to-severe Plaque Psoriasis
Secondary ID [1] 0 0
SHR-1314-A201
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Moderate-to-severe Chronic Plaque Psoriasis 0 0
Condition category
Condition code
Skin 0 0 0 0
Dermatological conditions
Skin 0 0 0 0
Other skin conditions

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - SHR-1314
Treatment: Drugs - Placebo

Experimental: 80mg SHR-1314-Part A - SHR-1314 80mg, subcutaneously

Experimental: 160mg SHR-1314-Part A - SHR-1314 160mg, subcutaneously

Experimental: 240mg SHR-1314-Part A - SHR-1314 240mg, subcutaneously

Experimental: 40mg SHR-1314 (Part B) - SHR-1314 40mg, subcutaneously

Experimental: 80mg SHR-1314 (Part B) - SHR-1314 80mg, subcutaneously

Experimental: 160mg SHR-1314 (Part B) - SHR-1314 160mg, subcutaneously

Experimental: 240mg SHR-1314 (Part B) - SHR-1314 240mg, subcutaneously

Experimental: SHR-1314 Placebo (Part B) - SHR-1314 Placebo, subcutaneously


Treatment: Other: SHR-1314
Administered subcutaneously

Treatment: Drugs: Placebo
Administered subcutaneously
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With Clinically Significant Events (Part A)
Timepoint [1] 0 0
From baseline through 24 weeks
Primary outcome [2] 0 0
Pharmacokinetics (PK) of SHR-1314 (Part A)
Timepoint [2] 0 0
From baseline through 24 weeks
Primary outcome [3] 0 0
Pharmacokinetics (PK) of SHR-1314 (Part A)
Timepoint [3] 0 0
From baseline through 24 weeks
Primary outcome [4] 0 0
Percentage of Participants With Anti-SHR-1314 Antibodies (Part A)
Timepoint [4] 0 0
From baseline through 24 weeks
Primary outcome [5] 0 0
Percentage of subjects who achieve Psoriasis Area Severity Index (PASI) score 75 (Part B)
Timepoint [5] 0 0
From baseline through 12 weeks
Secondary outcome [1] 0 0
Psoriasis Area Severity Index (PASI) score
Timepoint [1] 0 0
From baseline through 24 weeks (Part A) or 36 weeks (Part B)
Secondary outcome [2] 0 0
Physician's Global Assessment (PGA) of 0 or 1 achievement
Timepoint [2] 0 0
From baseline through 24 weeks (Part A) or 36 weeks (Part B)
Secondary outcome [3] 0 0
Change of dermatology life quality index (DLQI) score
Timepoint [3] 0 0
From baseline up to 12 weeks (Part A) or 36 weeks (Part B)
Secondary outcome [4] 0 0
Change from baseline in Body Surface Area (BSA)
Timepoint [4] 0 0
From baseline through 12 weeks (Part A) or (Part B)

Eligibility
Key inclusion criteria
Major

1. Provide written informed consent before any study assessment is performed.
2. Male or female at least 18 years of age at screening.
3. At the time of randomization, moderate to severe plaque psoriasis, defined by:

* PASI score of 12 or greater and
* PGA score of 3 or greater and
* BSA affected by plaque-type psoriasis of 10% or greater.
4. Subject is a candidate for systemic psoriasis therapy and/or phototherapy and/or chemo phototherapy.

Major
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic, and guttate psoriasis) at screening.
2. Drug-induced psoriasis (i.e. new onset or current exacerbation from beta-blockers, calcium channel inhibitors or lithium) at randomization.
3. Active systemic infections (other than common cold) during the two weeks before randomization (e.g., hepatitis), or serious infections requiring hospitalization and/or intravenous injection of antibiotic treatment within eight weeks from randomization.
4. Presence of other skin conditions (e.g. skin infections, seborrheic dermatitis) that in the judgement of the Investigator could interfere with assessment of psoriasis.
5. History of inflammatory bowel disease or have other ongoing active autoimmune diseases.
6. At screening, history or symptoms of malignancy of any organ system, treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
7. History of depression and/or suicidal ideation or behavior which in the opinion of the Investigator, makes the subject unsuitable for clinical study participation.
8. Any severe, progressive or uncontrolled medical condition at randomization that in the judgement of the Investigator prevents the subject from participating in the study.
9. Have a known allergy or hypersensitivity to any biologic therapy at screening that would pose an unacceptable risk to the subject if participating in this study.
10. Concurrent or recent use of psoriasis treatments/ medications.
11. Are currently enrolled in, or discontinued from a clinical trial involving an Investigational product (IP) within the last 4 weeks or at least 5 half-lives of the last dosing prior to randomization, whichever is longer; or concurrently enrolled (at randomization) in any other trials.
12. Have had a live attenuated vaccination within 12 weeks before randomization, or intend to have a live attenuated vaccination during the course of the study, or have participated in a vaccine clinical trial within 12 weeks prior to randomization.
13. Have evidence of positive test for hepatitis B, hepatitis C antibody, or human immunodeficiency virus (HIV) antibodies.

A positive test for hepatitis B is defined as 1) positive for hepatitis B surface antigen [HBsAg], or 2) positive for anti-hepatitis B core antibody [HBcAb+] but negative for hepatitis B surface antibody [HBsAb-].
14. History or evidence of active or latent tuberculosis at screening.
15. Have laboratory test values that are considered clinically significant at screening that, in the opinion of the Investigator, pose an unacceptable risk to the subject if participating in the study or of interfering with the interpretation of data.
16. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin laboratory test at screening or Day 0.
17. Females of child bearing potential (defined as all females physiologically capable of becoming pregnant) and males who are unwilling or unable to use highly effective contraception during the study and 20 weeks after the last administration of investigational product (anticipated 5 half-lives).
18. History of alcohol or illicit drug abuse within the year prior to screening.
19. Are unwilling or unable to maintain their normal pattern of alcohol, caffeine, smoking, and exercise from the start to the end of the study.
20. Have any other condition that precludes the subject from following and completing the protocol, in the opinion of the Investigator.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/12/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
31/08/2020
Sample size
Target
Accrual to date
Final
211
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
St George Dermatology and Skin Cancer Centre - Dermatology - Kogarah
Recruitment hospital [2] 0 0
Westmead Hospital - Westmead
Recruitment hospital [3] 0 0
Veracity Clinical Research Pty Ltd - Woolloongabba
Recruitment hospital [4] 0 0
Sinclair Dermatology - Dermatology - East Melbourne
Recruitment postcode(s) [1] 0 0
2217 - Kogarah
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [4] 0 0
3002 - East Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Rhode Island
Country [6] 0 0
United States of America
State/province [6] 0 0
Texas
Country [7] 0 0
China
State/province [7] 0 0
Shanghai

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Jiangsu HengRui Medicine Co., Ltd.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT03463187